贝伐单抗
医学
化疗
内科学
危险系数
肿瘤科
耐受性
卵巢癌
随机对照试验
卡铂
外科
癌症
不利影响
置信区间
顺铂
作者
Aris Bamias,Emma Gibbs,Chee Khoon Lee,Lucy Claire Davies,Meletios Athanasios Dimopoulos,Flora Zagouri,Anne-Sophie Veillard,Jens Kosse,Ana Santaballa,Mansoor Raza Mirza,Gianna Tabaro,Ignace B. Vergote,Haiko J. Bloemendal,Maria Lykka,Anne Floquet,Val Gebski,Éric Pujade-Lauraine
标识
DOI:10.1093/annonc/mdx228
摘要
In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomized to chemotherapy alone.In AURELIA, 361 women with PROC were randomized to chemotherapy alone or with bevacizumab. Patients initially randomized to chemotherapy were offered bevacizumab after PD. Post hoc analyses assessed efficacy and safety in three subgroups: chemotherapy alone, chemotherapy followed by bevacizumab after PD, and chemotherapy plus bevacizumab at randomization.Of the 182 patients randomized to chemotherapy alone, 72 (40%) received bevacizumab after PD and 110 (60%) never received bevacizumab. There were no significant differences in patient and disease characteristics between these subgroups at baseline or the time of PD. Compared with patients never receiving bevacizumab, the risk of death was significantly reduced in patients receiving bevacizumab either upfront with chemotherapy [hazard ratio (HR) = 0.68, 95% confidence interval (CI) 0.52-0.90] or after PD (HR = 0.60, 95% CI 0.43-0.86). The tolerability of bevacizumab was similar with administration upfront or after PD.Post-PD bevacizumab use may have confounded OS results in AURELIA. In these exploratory analyses of non-randomized subgroups, bevacizumab use, either with chemotherapy or after PD on chemotherapy alone, improved OS compared with no bevacizumab. Combining bevacizumab with chemotherapy at first appearance of platinum resistance maximises the likelihood of patients receiving this active treatment for PROC. ClinicalTrials.gov: NCT00976911.
科研通智能强力驱动
Strongly Powered by AbleSci AI